NCT03039972

Brief Summary

Changes in renal function and body composition in patients with pulmonary hypertension

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 25, 2017

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 29, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 1, 2017

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 7, 2019

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 9, 2020

Completed
Last Updated

December 17, 2020

Status Verified

December 1, 2020

Enrollment Period

2.7 years

First QC Date

January 29, 2017

Last Update Submit

December 14, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in renal function in patients with pulmonary hypertension

    Estimated GFR based on Chronic Kidney Disease Epidemiology Collaboration-creatinine-cystatin C will be used to determine renal function at baseline and at 1 year follow-up

    1 year

Secondary Outcomes (3)

  • Changes in hydration status in patients with pulmonary hypertension

    1 year

  • Changes in nutritional status in patients with pulmonary hypertension

    1 year

  • Prognostic value of baseline renal function, hydration and nutritional status on pulmonary hypertension-associated morbidity and mortality

    1 year

Study Arms (1)

Pulmonary Hypertension

Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages

Diagnostic Test: No intervention

Interventions

No interventionDIAGNOSTIC_TEST

No intervention

Pulmonary Hypertension

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All patients with suspected or pre-diagnosed pulmonary hypertension at pulmonary hypertension outpatient clinic, University Hospital Giessen and Marburg, Campus Giessen

You may qualify if:

  • Subjects older than 18 years at pulmonary hypertension outpatient clinic
  • Subjects who signed informed consent forms

You may not qualify if:

  • Patients refusing to participate or withdraw consent during follow-up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Clinic Giessen and Marburg - Campus Giessen

Giessen, Hesse, 35392, Germany

Location

Related Publications (4)

  • Bellomo R, Prowle JR, Echeverri JE. Diuretic therapy in fluid-overloaded and heart failure patients. Contrib Nephrol. 2010;164:153-163. doi: 10.1159/000313728. Epub 2010 Apr 20.

    PMID: 20428001BACKGROUND
  • Ronco C, Verger C, Crepaldi C, Pham J, De Los Rios T, Gauly A, Wabel P, Van Biesen W; IPOD-PD Study Group. Baseline hydration status in incident peritoneal dialysis patients: the initiative of patient outcomes in dialysis (IPOD-PD study)dagger. Nephrol Dial Transplant. 2015 May;30(5):849-58. doi: 10.1093/ndt/gfv013. Epub 2015 Mar 11.

    PMID: 25762355BACKGROUND
  • Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol. 2014 May;9(5):855-63. doi: 10.2215/CJN.10191013. Epub 2014 Feb 27.

  • Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009 Feb 17;53(7):582-588. doi: 10.1016/j.jacc.2008.08.080.

Biospecimen

Retention: SAMPLES WITH DNA

Collection of only residual material (blood, urine) for Deutsche Zentrum für Lungenforschung Biobank.

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Officials

  • Werner Seeger, MD

    Department of Internal Medicine II, Division of Pulmonology, Nephrology and Critical Care Medicine

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Physician Nephrology

Study Record Dates

First Submitted

January 29, 2017

First Posted

February 1, 2017

Study Start

January 25, 2017

Primary Completion

October 7, 2019

Study Completion

July 9, 2020

Last Updated

December 17, 2020

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will share

All IPD that underlie results in a publication

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Starting 6 months after publication

Locations